An observational study in Endometriosis, sponsored by Wren Laboratories LLC. Enrolling by invitation at 3 sites in 2 countries. Open to female participants aged 20 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Wren Laboratories LLC · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 169 studies in Endometriosis with a site in United States — 38 open to participants now, 48 under way, 5 of them phase 3. Endometriosis · United States.
Among the 169 studies in Endometriosis with a site in United States, this one is the 14th largest by planned enrollment of the 38 observational ones that give a count, is one of 11 that started in 2024, is one of 38 observational ones, reaches primary completion later than 33 of the 47 other live ones, and was the 150th registered.
924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →38 of the 169 studies in Endometriosis with a site in United States are open now. Recruiting first, the newest first:
SWIMS America Corp. · Sites in United States
Ages 18+ · Women only
LOAM Science · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
Milton S. Hershey Medical Center · Sites in United States
Ages 18–45
Christiana Care Health Services · Sites in United States
Ages 18+ · Women only
Staci Gruber, Ph.D. · Sites in United States
Ages 21+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 20 Years to 35 Years · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
169 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 45 · Phase 3 22 · Phase 4 14
First in 1998; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 132 across 351 observational studies indexed under Endometriosis.
Median enrollment 60 across the 131 interventional studies, 187 across the 38 observational. Of the 102 that completed or were terminated, 50 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 169 have an industry lead sponsor. The 10 most frequent:
Wren Laboratories LLC is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Wren Laboratories LLC has 1 study filed under Endometriosis — fewer than ten, so there is no comparison to draw.
23 of the studies in Endometriosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06375811Phase 3Yale UniversityPre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp | 2027-03-31 |
| NCT04333576Phase 3AbbVieStudy Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain | 2027-07 |
| NCT05245695Aspira Women's HealthDeep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck) | 2026-11-30 |
| NCT06477406Mclean HospitalEvaluating the Impact of a Novel Cannabinoid Product for Endometriosis | 2026-12 |
| NCT05059626Penn State UniversityEndometriosis and Microvascular Dysfunction; Simvastatin and Duavee | 2026-12-31 |
Add all 23 to your calendar (.ics) → With an account.
Among the 169 studies in Endometriosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Endometriosis is a common disease that affects up to 10% of women of reproductive age. Diagnosis, however, is typically delayed (up to 12 years) and is usually made after surgery. A key unmet need therefore is an accurate biomarker that can be used to detect the disease early. This study is a prospective trial to identify candidate mRNA-markers which can be used to aid in the diagnosis of this disease. It is a discovery/validation study that will identify and confirm a gene expression panel that is specific for endometriosis and provides a non-invasive tool for future use.
Endometriosis is a common disease that affects up to 10% of women of reproductive age. Diagnosis, however, is typically delayed (up to 12 years) and is typically made after surgery. A key unmet need therefore is an accurate, non-invasive biomarker that can be used to detect the disease early.
We hypothesize that endometriosis-related circulating gene expression can be identified using transcriptomic and bioinformatics approaches and used to construct an accurate diagnostic tool for this condition.
The primary objective is to develop a gene signature that detects endometriosis. The hypothesis is that this disease is characterized by a set of genes that characterize endometriosis tumor biology.
The aim is to detect over-expressed genes (elevated mRNA expression) in endometriosis tissue. The goal is to identify 10-25 biomarker genes that are highly expressed to form a candidate biomarker panel.
Highly expressed genes will be determined against samples collected from age/menstrual stage matched controls. A bio-informatics approach will be used to identify these over-expressed genes. This form the basis of a potential diagnostic panel.
Per PICOT criteria:
The secondary objective is to test the diagnostic utility of the 10-25 gene panel. This will be undertaken using the retrospectively collected samples.
The metrics for a successful assay are:
Women with high suspicion of endometriosis and women undergoing surgery for benign cervical disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For the endometriosis cohort
Inclusion criteria for controls include normo-ovulatory history, aged between 20-35 years, who exhibit normal liver and kidney function, and do not have any systemic diseases including disease.
-
Exclusion Criteria:
For the endometriosis cohort
Exclusion criteria for the controls includes gynaecological malignancies and genital tuberculosis.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women with suspected endometriosis undergoing laparoscopy to provide tissue for pathological diagnosis of the disease.
Diagnostic Test: EndoDx
Women undergoing surgery for benign cervical disease.
Diagnostic Test: EndoDx
PCR assay for Endometriosis diagnosis
Develop a gene signature that detects endometriosis
Gene expression levels in samples from endometriosis subjects and controls
Time frame: 12-18 months
Assess the diagnostic utility of the gene signature to differentiate between endometriosis and controls
Algorithmic analysed normalized gene expression levels in samples from endometriosis subjects and controls
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Aug 2028, 55 months after the start.
Of 185 observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 55 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Aug 2025 → Aug 2028 and completion Dec 2026 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wren Laboratories LLC